newsfilter
← Latest News
GlobeNewswire·

Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update

– NL-201 Phase 1 solid tumor trial interim data anticipated in 2022 – – Upcoming presentations at ACR, SITC, and ASH to highlight preclinical data – – Planning to initiate a Phase 1 trial in hematologic malignancies with NL-201 in